TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12789182
Drug: Dermasanding treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermasanding treatment
Study: 10663454
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 2.5 mg orally, q.d. for 8 days
Study: 10663454
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 10 mg orally, q.d. for 8 days
Study: 10663454
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 20 mg orally, q.d. for 8 days
Study: 10663454
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 (oral solution)
Study: 8801396
Drug: Lovastatin (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20-80 mg/day)
Study: 6849734
Drug: Bedtime chenic
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime chenic acid 8 mg kg‐1 day‐1
Study: 6849734
Drug: Sodium acetyl
Normalized name: sodium acetyltryptophanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium acetyl salicylate 600 mg four times daily
Study: 6849734
Drug: Bedtime chenic
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime chenic acid 8 mg kg‐1 day‐1 plus sodium acetyl salicylate
Study: 31399378
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella zoster virus vaccine (VZV)
Study: 27749141
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of haloperidol and midazolam
Study: 22779281
Drug: Oral-B Precision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Precision Clean (PC) brush head
Study: 17929519
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading (4 months after implant insertion)
Study: 17929519
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading (1 week after implant surgery)
Study: 11257249
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg weekly
Study: 11257249
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice a week
Study: 11257249
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice a week for 12 weeks followed by 30 mg weekly
Study: 11257249
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice a week for 6 weeks followed by 30 mg weekly
Study: 11257249
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg weekly
Study: 11257249
Drug: Single 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 60 mg loading dose followed by 30 mg weekly doses
Study: 11257249
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg weekly (Dosage regimen VI)
Study: 11257249
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice a week for 12 weeks (Dosage regimen III)
Study: 9886194
Drug: Artesunate (2mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (2mg/kg/day for five days, then 1 mg/kg/day for two days: total=12 mg/kg)
Study: 9886194
Drug: Artemether (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (4 mg/kg followed by 2 mg/kg/day for two days, then 1 mg/kg/day for four days: total=12 mg/kg)
Study: 8002848
Drug: Drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention to lower cholesterol levels
Study: 7698136
Drug: Ramipril (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (titrated from 1.25 mg to a maximum of 10 mg once daily over 4 weeks, mean dose 8 mg)
Study: 699938
Drug: Intravenous practolol
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous practolol 15 mg followed by oral practolol 200 mg at 12 h intervals
Study: 699938
Drug: Intravenous practolol
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous practolol
Study: 22436475
Drug: Intra-articular lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lidocaine (IAL) - 4 mg/kg (up to 200 mg) of 1% lidocaine injected into the glenohumeral joint.
Study: 22436475
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (IVS) - medications for sedation as per physician discretion.
Study: 19018157
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 50 mg weekly
Study: 11842271
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate supplementation (5-day load of 0.3 g/kg(-1) x day(-1) followed by a 5-week maintenance dose of 0.03 g/kg(-1) x day(-1))
Study: 11842271
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate supplementation (5-week maintenance dose)
Study: 9788454
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 to 5.00 mg/day)
Study: 9788454
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conventional antihypertensive therapy
Study: 2969551
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy combined with anti-thrombosis stockings
Study: 31226238
Drug: Bioabsorbable implant
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable implant (Latera)
Study: 25029005
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg.kg of body mass
Study: 25029005
Drug: Caffeine 10
Normalized name: caffeine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 10 mg.kg of body mass
Study: 25029005
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg.kg of body mass)
Study: 15237655
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (300 ml per day for 72 hours)
Study: 15237655
Drug: HES 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 500 ml (per day for 72 hours)
Study: 15237655
Drug: HES 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 1000 ml (per day for 72 hours)
Study: 15237655
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1000 ml per day for 72 hours)
Study: 11236257
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (40 patients with stabilized UA after pharmacological treatment)
Study: 8800298
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50, 10, 2, 0.4 micrograms/g)
Study: 1735081
Drug: 5-fluorouracil (5-FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks, modulated sinusoidally over 24 hours.
Study: 1735081
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate modulated according to circadian rhythms.
Study: 1735081
Drug: 5-fluorouracil (5-FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks.
Study: 3883700
Drug: Antacid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid treatment (10 ml of an antacid suspension seven times a day, buffering 367.5 mmol acid)
Study: 28739263
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg)
Study: 28739263
Drug: Repeated treatments
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatments of subcutaneous ketamine
Study: 16866794
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25 microg every 3 h (group 1, n = 100)
Study: 16866794
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol followed by oxytocin (group 2, n = 100)
Study: 16866794
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (group 1)
Study: 14678208
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg nickel sulfate hexahydrate
Study: 14678208
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nickel sulfate hexahydrate
Study: 14678208
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg nickel sulfate hexahydrate
Study: 10520053
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen allergoid immunotherapy (IT) plus symptomatic treatment
Study: 1822906
Drug: Praziquantel 50
Normalized name: praziquantel 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 50 mg/kg/day for 15 days
Study: 1822906
Drug: Albendazole 15
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 15 mg/kg/day for 30 days
Study: 6456140
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin base 2%
Study: 26971543
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (ET)
Study: 23519054
Drug: Herbal mucoadhesive
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Herbal mucoadhesive tablets
Study: 23519054
Drug: Placebo mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mucoadhesive tablets
Study: 21184622
Drug: Nilotinib 800
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 800 mg
Study: 21184622
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg alone (placebo control)
Study: 18808378
Drug: Topical betulin-based
Normalized name: betulin
DrugBank: Betulin (DB16890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betulin-based oleogel twice daily
Study: 18808378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cryotherapy with topical betulin-based oleogel
Study: 9702934
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg titrated to losartan 50 mg/hydrochlorothiazide (HCT) 12.5 mg
Study: 9702934
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg titrated to 10 mg
Study: 30650444
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of ADP to agonist in obese patients and SERCA3-inhibited control platelets
Study: 21073363
Drug: Eplerenone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (up to 50 mg daily)
Study: 18341017
Drug: ROM (rifampicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM (rifampicin, ofloxacin, and minocycline) administered by body weight to adults above 15 years; RMP (rifampicin) administered by body weight to children below 15 years.
Study: 18341017
Drug: Vitamins administered
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins administered to non-treated group.
Study: 16818928
Drug: Cysticidal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysticidal drug therapy
Study: 14505199
Drug: Transmeatal cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmeatal cochlear laser treatment (TCL) using diode lasers (lambda=635 nm, 7.8 mW cw, n=17 and lambda=830 nm, 20 mW cw, n=18) with a space irradiation of 4 J/cm2 at the site of maximal cochlear injury.
Study: 14505199
Drug: Transmeatal cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmeatal cochlear laser treatment (TCL)
Study: 6864076
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy for 2 weeks
Study: 17585028
Drug: Total urinary
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total urinary excretion
Study: 12214463
Drug: TAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP therapy (TXL 160 mg/m2 3 h, day 2, ADM 45 mg/m2, day 1, CDDP 50 mg/m2 day 1)
Study: 12214463
Drug: AP therapy
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP therapy (ADM 60 mg/m2, CDDP 50 mg/m2)
Study: 12078199
Drug: 3 tablets
Normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of albendazole composite
Study: 12078199
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of albendazole composite
Study: 12078199
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg of albendazole
Study: 12078199
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 mg base/kg of pyrantel pamoate
Study: 12078199
Drug: 1.5 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 tablets of albendazole composite
Study: 12078199
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pyrantel pamoate
Study: 2686955
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g) administered as i.v. bolus 30 min before operation
Study: 2686955
Drug: Piperacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2 g) administered as i.v. bolus 30 min before operation
Study: 28363687
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment strategy with angiographic guidance (n=450)
Study: 28363687
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment strategy with angiographic guidance (n=449)
Study: 28363687
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment strategy
Study: 26131189
Drug: LJCT (Lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJCT (Lower Joint Cavity Treatment)
Study: 26131189
Drug: UJCT (Upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: UJCT (Upper Joint Cavity Treatment)
Study: 16467019
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg daily for at least 60 days
Study: 16467019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only emollients for topical therapy)
Study: 11288031
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (50 mU/kg/h) for 4 hours
Study: 8461565
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) administered continuously
Study: 8461565
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) administered cyclically
Study: 8461565
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) administered cyclically (50-60 mg/day)
Study: 3488178
Drug: Fibrin sealing
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealing for treatment of manifest lymph fistulae (n = 9)
Study: 27524190
Drug: CEE+ MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+ MPA sequential therapy
Study: 27524190
Drug: E2V+ MPA
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V+ MPA sequential therapy
Study: 27524190
Drug: E2V+ P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V+ P sequential therapy
Study: 18580019
Drug: Antibiotic-lock therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-lock therapy using vancomycin and gentamycin
Study: 16197624
Drug: Irinotecan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 200 mg/m2 on day 1, levo-leucovorin (LV) 250 mg/m2, and 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2
Study: 879070
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing cystine at 6 mg/100 ml
Study: 879070
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing cystine at 28 mg/100 ml
Study: 879070
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of tyrosine less than 50 mg/kg of body weight
Study: 23542637
Drug: valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valacyclovir 1000 mg twice daily
Study: 23542637
Drug: acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir 400 mg twice daily
Study: 21884720
Drug: Carisoprodol 700
Normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisoprodol 700 mg
Study: 19908948
Drug: Carisoprodol 350
Normalized name: carisoprodol 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisoprodol 350 mg
Study: 21884720
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg carisoprodol)
Study: 14659122
Drug: Mastectomy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy or breast conservation with or without radiation therapy
Study: 1412641
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg body weight) + Desipramine (1.3-2.8 mg/kg body weight) daily for 3 days
Study: 3874641
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg kg‐1
Study: 3874641
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 mg kg‐1
Study: 3874641
Drug: Methohexitone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 1.5 mg kg‐1
Study: 28502186
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with VP, indomethacin, and treatment of bacterial vaginosis (BV)
Study: 28502186
Drug: Dydrogesterone, 17-OH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone, 17-OH progesterone (17OHP), and micronized oral progesterone (OP)
Study: 26242382
Drug: JNJ‐54452840 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐54452840 20 mg
Study: 26242382
Drug: JNJ‐54452840 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐54452840 80 mg
Study: 26242382
Drug: JNJ‐54452840 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐54452840 240 mg
Study: 22686076
Drug: Xinganbao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinganbao Capsule (8 capsules, three times a day)
Study: 22686076
Drug: Heluo Shugan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heluo Shugan Tablet (5 pills, thrice daily)
Study: 16580386
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg daily plus oral contraceptive pill (OCP)
Study: 27488933
Drug: Ramosetron 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.6 mg
Study: 10648342
Drug: Ramosetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.15 mg
Study: 14749148
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg vs Ramosetron 0.6 mg
Study: 6778197
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg/day
Study: 31143922
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear worn for 12 hours daily
Study: 29540069
Drug: Carbon monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon monoxide inhalation (carboxyhemoglobin 22%)
Study: 12675644
Drug: Intensified management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified management with diet, exercise, and insulin
Study: 10872954
Drug: Continuous non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous non-surgical therapy (one or more non-surgical procedures performed during 3 successive years)
Study: 10872954
Drug: Intermittent non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent non-surgical therapy
Study: 2008547
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TNS)
Study: 1844692
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects across centers
Study: 31850484
Drug: Combined mouthwash
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mouthwash formulation containing natural antibiofilm agents
Study: 31850484
Drug: Combined mouthwash
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mouthwash formulation